CPHI 2025

The conversation starts here

Amid economic pressures, regulatory shifts, and rising complexity, the need for reliable, agile partners has never been greater. At CPHI Frankfurt 2025, we’re bringing together global expertise, integrated capabilities, and scientific depth to help you keep progress moving—wherever you are in the world, in your program, or in the face of disruption.

CPHI Frankfurt 2025

Visit the conference website

Why visit us at CPHI?

Whether you’re planning your first IND or running complex clinical trials, Accelerator™ Drug Development, 360° CDMO and CRO solutions are designed to flex with your needs and reduce development and clinical research friction. Visit us at the Thermo Fisher Scientific booth #5.1A8 or schedule a meeting with our experts to explore how our GMP laboratory services are designed to support you across all phases of development. With our global reach and a commitment to partnership, we help streamline transitions between phases, shorten timelines, and provide clarity in a world of constant change.

Let’s talk about how we can help you:

Navigate global complexity with geographic agility and regulatory foresight
Build seamless pathways from early development through commercialization
Determine the right analytical services to shorten timelines
Adapt to evolving market demands without losing momentum
Stay aligned across phases, functions, and teams

By connecting development, manufacturing, bioprocessing, clinical supply services, clinical trial management and GMP laboratory services, we bring the clarity and continuity you need to move forward faster and with confidence.

Let’s start the conversation in Frankfurt.

Schedule a meeting

Mark your calendar for this can’t miss session

“What’s your next move—and what will it cost you? Driving value under pressure”

Date: Wednesday, October 29, 2025
Time: 1:30 – 1:55 p.m. CET (25 minutes)
Location: Hall 4.1 – 4.1L8

Featuring Jennifer Cannon, President of Commercial Operations, Thermo Fisher Scientific

In this environment, traditional development models can slow progress, increase risk, and quietly drain time, money, and competitive advantage from a program. This session will examine a development model that’s reshaping expectations by unifying scientific, manufacturing, and clinical execution to unlock value at every stage.

Attendees will learn:

Where disjointed execution models create risk, delays, and added cost in drug development
What new data reveals about the ROI and timeline advantages of coordinated outsourcing
How companies are adjusting execution strategies to maintain momentum under pressure